[
    [
        {
            "time": "",
            "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "2021年"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
            "features": {
                "keywords": [
                    "医药",
                    "白酒",
                    "2021年度策略",
                    "次新股",
                    "圣农发展"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药生物",
                    "投资策略",
                    "2021年"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]